medigraphic.com

2010, Number 4

<< Back Next >>

Cir Cir 2010; 78 (4)

Collagen-polyvinylpyrrolidone: a new therapeutic option for treatment of sequelae as a result of radical mastectomy in women with breast cancer. Preliminary study

Ruiz-Eng R, Montiel-Jarquín A, de la Rosa-Pérez R, López-Colombo A, Gómez-Conde E, Zamudio-Huerta L

Language: Spanish
References: 22
Page: 310-314
PDF size: 244.60 Kb.


ABSTRACT

Background: Approximately 30% of women who undergo mastectomy without reconstructive treatment due to breast cancer present sequelae. These include paresthesias, keloid healing, hypoesthesia, lymphedema and limitation of the function of the ipsilateral upper extremity. We undertook this study to present the results using collagen-polyvinylpyrrolidone (Clg- Pvp) as treatment for posmastectomy sequelae in women with breast cancer.
Methods: We conducted a unicentric, longitudinal and prospective clinical trial between August 1, 2007 and July 31, 2008. Included variables were age, lymphedema, limitation of the function of the ipsilateral upper extremity, collapse of the wound, keloid healing, paresthesias, and appearance of the surgical area. The appearance of the surgical area (aesthetic aspect) was evaluated before and 6 months after treatment was initiated. Clg-Pvp was administered weekly for a 6-month period.
Results: Seven women were included with a median age of 49 years (range: 40-72 years). One patient (14.28%) presented lymphedema, two patients (28.57%) presented collapse of the wound, two patients (28.57%) had keloid healing, three patients (42.85%) experienced paresthesias, five patients (71.4%) reported pain, and five patients (71.4%) reported limitation of the function of the ipsilateral upper extremity. At the completion of the treatment, aesthetic improvement was statistically significant (p = 0.0020, Mann-Whitney U test).
Conclusions: Clinical and aesthetic results are good after application of Clg-Pvp for treating sequelae in women with breast cancer who underwent mastectomy without reconstructive surgery.


REFERENCES

  1. Latorre J, Davins M, Barreiro J, Sánchez I. Linfedema postmastectomía. Ann Cir Car Vasc 2005;11:22-37.

  2. Barriga C, Saa E, Camacho J, Adauy A, Ilabaca J, Muñoz M. Reconstrucción mamaria postmastectomía. Rev Chil Cir 2005;57:40-44.

  3. Gallegos-Hernández JF. Linfadenectomía selectiva del ganglio centinela en pacientes con cáncer de mama. Una alternativa a la disección radical de axila. Acta Med Grupo Angeles 2003;1:1.

  4. Gallager PG. Post-mastectomy edema and recurrent cellulitis: prevention and treatment. Vasc Surg 1986;20:368-386.

  5. Shons AR, Mosiello G. Postmastectomy breast reconstruction. Current techniques. Cancer Control 2001;8:419-426.

  6. Sneeuw KC, Aaronson NK, Yarnold JR, Broderick M, Regan J, Ross G, Goddard A. Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. Radiother Oncol 1992;25:153-159.

  7. González-Viejo MA. Tratamiento del linfedema y MBE. II Curso deevidencia científica en rehabilitación y medicina física. Bol Oncol 2006,26:756-798.

  8. Pecking AP, Février B, Wargon C. Efficacy of Daflon 500 mg in the treatment of lymphedema secondary to conventional therapy of breast cancer. Angiology 1997;48:93-98.

  9. Berenguer B, Gallo P, Rodríguez U, Marín G. Transplante libre de grasa para el tratamiento de la enfermedad de Parry Romberg infantil. Cir Pediatr 2005;18:49-5l.

  10. Krotzsch-Gómez FE, Furuzawa-Carballeda J, Reyes-Márquez R, Quiroz-Hernández E, Díaz de León L. Cytokine expression is downregulated by collagen-polyvinylpyrrolidone in hypertrophic scars. J Invest Dermatol 1998;3:828-834.

  11. Furuzawa-Carballeda J, Rodríguez-Calderón R, Díaz de León L, Alcocer- Varela J. Mediators of inflammation are down-regulated while apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized collagen. Clin Exp Immunol 2002;130:140-149.

  12. Bermúdez-Hickey R, Nesme-Ávila W, Ruiz-Flores L, Suárez E. Tratamiento de la pseudoartrosis de tibia con colágeno-polivinilpirrolidona. Rev Mex Ortop Trauma 1999;13:148-151.

  13. Schafmayer A, Osterloh B, Olschewski M, Willenbrock C, Gatzemeier W, Rauschecker H. Quality of life following surgery of breast cancer. Chirurg 1989;60:458-463.

  14. Celen O, Yildirim E, Berberoğlu U. Prevention of wound edge necrosis by local application of dimethylsulfoxide. Acta Chir Belg 2005;105:287-290.

  15. Paul MD. Primary breast reconstruction with a subpectoral silicone tissue expander. Ann Plast Surg 1985;15:404-414.

  16. Kontos M, Petrou A, Prassas E, Tsigris C, Roy P, Trafalis D, et al. Pressure dressing in breast surgery: is this the solution for seroma formation?J BUON 2008;13:65-67.

  17. Tsai R J, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott- Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 2009;16:1959-1572.

  18. Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, et al. Incidence, treatment costs, and complications of lymphedema afterbreast cancer among women of working age: a 2-year follow-up study. J Clin Oncol 2009;27:2007-2014.

  19. Baisch A, Riedel F. Hyperplastic scars and keloids: II: Surgical andnon-surgical treatment modalities. HNO 2006;54:981-992; quiz 993- 994.

  20. Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars andkeloids. A review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009;35:171-181.

  21. Serrano-Grau P, Mascaró-Galy JM, Iranzo P, Navarra E, Ferrando J. Productos de relleno inyectables en dermocosmética. Tipos y efectos secundarios. Med Cutan Iber Lat Am 2007;35:209-218.

  22. Bergeret-Galley C, Latouche X, Illouz YG. The value of a new filler material in corrective and cosmetic surgery: dermaLive and DermaDeep. Aesthetic Plast Surg 2001;25:249-255.




2020     |     www.medigraphic.com